Article thumbnail
Location of Repository

Predicted coverage based on in vitro neutralizing activity of VRC01.

By Kenneth H. Mayer (116219), Kelly E. Seaton (603000), Yunda Huang (235282), Nicole Grunenberg (662181), Abby Isaacs (4591450), Mary Allen (742378), Julie E. Ledgerwood (253787), Ian Frank (10438), Magdalena E. Sobieszczyk (332353), Lindsey R. Baden (189735), Benigno Rodriguez (89118), Hong Van Tieu (2190166), Georgia D. Tomaras (164058), Aaron Deal (4591447), Derrick Goodman (4591453), Robert T. Bailer (241545), Guido Ferrari (164054), Ryan Jensen (2806675), John Hural (173295), Barney S. Graham (194312), John R. Mascola (229761), Lawrence Corey (140058) and David C. Montefiori (108747)


<p>Predicted coverage based on in vitro neutralizing activity of VRC01.</p

Topics: Medicine, Microbiology, Neuroscience, Pharmacology, Immunology, Cancer, Mental Health, Infectious Diseases, Virology, Computational Biology, Chemical Sciences not elsewhere classified, dose, peak serum VRC 01 levels, HVTN, findings HIV Vaccine Trials Network, 249 IV infusions, treatment group 1, treatment group 3, Serum VRC 01 levels, 208 SC injections, Trial registration Clinical Trials Registration, mg, Conclusions VRC 01, CD 4 binding site, VRC 01 concentrations, anti-VRC 01 antibodies, 8 weeks, CI, 2 weeks, VRC 01 administration regimen, 6 United States, SHIV, treatment group 2, simian-human immunodeficiency virus, placebo group 3, IC, IV infusion series, VRC 01, phase 1 randomized trial Background VRC 01, NCT, VRC 01 administration
Year: 2017
DOI identifier: 10.1371/journal.pmed.1002435.t003
OAI identifier:
Provided by: FigShare
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • (external link)
  • Suggested articles

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.